FI903154A0 - KIMERISKA GLYKOPROTEINER INNEHAOLLANDE IMMUNOGENISKA SEGMENT AV GLYKOPROTEINER AV MAENNISKANS RESPIRATORY SYNCYTIAL VIRUS. - Google Patents

KIMERISKA GLYKOPROTEINER INNEHAOLLANDE IMMUNOGENISKA SEGMENT AV GLYKOPROTEINER AV MAENNISKANS RESPIRATORY SYNCYTIAL VIRUS.

Info

Publication number
FI903154A0
FI903154A0 FI903154A FI903154A FI903154A0 FI 903154 A0 FI903154 A0 FI 903154A0 FI 903154 A FI903154 A FI 903154A FI 903154 A FI903154 A FI 903154A FI 903154 A0 FI903154 A0 FI 903154A0
Authority
FI
Finland
Prior art keywords
glykoproteiner
respiratory syncytial
syncytial virus
maenniskans
kimeriska
Prior art date
Application number
FI903154A
Other languages
Finnish (fi)
Other versions
FI102382B (en
FI102382B1 (en
Inventor
Michael Wathen
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of FI903154A0 publication Critical patent/FI903154A0/en
Application granted granted Critical
Publication of FI102382B publication Critical patent/FI102382B/en
Publication of FI102382B1 publication Critical patent/FI102382B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention encompasses DNA compositions encoding novel chimeric glycoproteins which are useful for preparing virus specific immune responses against human respiratory syncytial virus. The DNA compositions include structural genes coding for the glycoproteins and expression and replication plasmids containing the structural genes. Host cells transformed with the above DNA compositions, vaccines made from the glycoproteins and methods for protecting humans by inoculation with said vaccines are also part of this invention.
FI903154A 1987-12-23 1990-06-21 Expression system for chimeric glycoproteins containing immunogenic fragments of human respiratory syncytial virus glycoproteins FI102382B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13738787A 1987-12-23 1987-12-23
US13738787 1987-12-23
US8803784 1988-10-31
PCT/US1988/003784 WO1989005823A1 (en) 1987-12-23 1988-10-31 Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus

Publications (3)

Publication Number Publication Date
FI903154A0 true FI903154A0 (en) 1990-06-21
FI102382B FI102382B (en) 1998-11-30
FI102382B1 FI102382B1 (en) 1998-11-30

Family

ID=22477194

Family Applications (1)

Application Number Title Priority Date Filing Date
FI903154A FI102382B1 (en) 1987-12-23 1990-06-21 Expression system for chimeric glycoproteins containing immunogenic fragments of human respiratory syncytial virus glycoproteins

Country Status (14)

Country Link
US (2) US5194595A (en)
EP (1) EP0396563B1 (en)
JP (1) JP2716503B2 (en)
KR (1) KR0137963B1 (en)
AT (1) ATE85622T1 (en)
AU (1) AU617739B2 (en)
CA (1) CA1320163C (en)
DE (1) DE3878468T2 (en)
DK (1) DK173175B1 (en)
FI (1) FI102382B1 (en)
HK (1) HK166295A (en)
MX (1) MX9203458A (en)
NO (1) NO300254B1 (en)
WO (1) WO1989005823A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8914968D0 (en) * 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
US6004563A (en) * 1990-11-07 1999-12-21 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
TW275632B (en) * 1992-04-21 1996-05-11 American Cyanamid Co
WO1994015968A1 (en) * 1993-01-08 1994-07-21 The Upjohn Company Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein
JP3734263B2 (en) * 1993-05-25 2006-01-11 ワイス・ホールディングズ・コーポレイション Adjuvants for vaccines against respiratory syncytial virus
ES2344643T3 (en) * 1994-01-14 2010-09-02 Matthias Dr. Med. Rath HYDROPHILIC SIGNAL OLIGOPEPTIDES AND THERAPEUTIC USE METHODS.
US7300918B2 (en) 1994-01-14 2007-11-27 Matthias Rath Method of producing vaccines from protein signal oligopeptides
FR2718452B1 (en) * 1994-04-06 1996-06-28 Pf Medicament Element of immunogen, immunogenic agent, pharmaceutical composition and method of preparation.
WO1996010400A1 (en) * 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
FR2726472B1 (en) * 1994-11-07 1997-01-31 Pf Medicament CARRIER WITH ADJUVANT EFFECT, IMMUNOGENIC COMPLEX CONTAINING THE SAME, PREPARATION METHOD THEREOF, NUCLEOTIDE SEQUENCE AND VACCINE
DE4442114A1 (en) * 1994-11-25 1996-05-30 Buna Sow Leuna Olefinverb Gmbh Nitrite, phosphate and amine free coolant and heat transfer medium
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6015664A (en) * 1995-11-03 2000-01-18 Mcw Research Foundation Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B
WO1998018819A1 (en) * 1996-10-29 1998-05-07 Smithkline Beecham Biologicals S.A. Purification of respiratory syncytial virus antigens
US20070067859A1 (en) * 1997-07-14 2007-03-22 Michel Georges Double-muscling in mammals
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
PT2045322E (en) * 1997-07-14 2015-10-16 Université de Liège Double-muscling in mammals
US6699478B1 (en) * 1997-09-19 2004-03-02 Wyeth Holdings Corporation Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
DE60142614D1 (en) * 2000-01-27 2010-09-02 Medimmune Inc INITÄT
DK1259547T3 (en) * 2000-03-01 2012-10-15 Medimmune Inc HIGH POTENTIAL, RECOMBINANT ANTIBODIES AND PROCEDURE FOR PRODUCING THEM
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
DE602005018473D1 (en) * 2004-05-24 2010-02-04 Polymun Scient Immunbio Forsch SUPER-LOADED LIPOSOME FOR DRUG DELIVERY
EP1812068A4 (en) * 2004-10-29 2010-06-09 Medimmune Inc Methods of preventing and treating rsv infections and related conditions
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP4219566A3 (en) 2007-12-24 2023-09-06 ID Biomedical Corporation of Quebec Recombinant rsv antigens
MX2011000668A (en) * 2008-07-18 2011-07-29 Id Biomedical Corp Quebec Chimeric respiratory syncytial virus polypeptide antigens.
AU2010264688A1 (en) 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Recombinant RSV antigens
CN105214080A (en) 2009-07-15 2016-01-06 诺华股份有限公司 RSV F protein compositions and its manufacture method
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US9480738B2 (en) 2012-08-01 2016-11-01 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (MVA) respiratory syncytial virus (RSV) vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855224A (en) * 1984-03-09 1989-08-08 Genentech, Inc. Molecularly cloned diagnostic product and method of use
AU605476B2 (en) * 1986-01-14 1991-01-17 University Of North Carolina, The Vaccines for human respiratory virus
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
US5001230A (en) * 1988-02-18 1991-03-19 Schering Corporation T cell activation markers
SG106639A1 (en) * 2000-10-10 2004-10-29 Gen Electric Apparatus and method for introducing small amounts of refractory elements into a vapor deposition coating

Also Published As

Publication number Publication date
DK173175B1 (en) 2000-03-06
JP2716503B2 (en) 1998-02-18
MX9203458A (en) 1992-09-01
FI102382B (en) 1998-11-30
EP0396563B1 (en) 1993-02-10
NO902802L (en) 1990-06-22
DE3878468D1 (en) 1993-03-25
ATE85622T1 (en) 1993-02-15
AU617739B2 (en) 1991-12-05
KR900700508A (en) 1990-08-13
NO300254B1 (en) 1997-05-05
JPH03501723A (en) 1991-04-18
EP0396563A1 (en) 1990-11-14
DE3878468T2 (en) 1993-06-09
AU2785089A (en) 1989-07-19
NO902802D0 (en) 1990-06-22
KR0137963B1 (en) 1998-04-30
FI102382B1 (en) 1998-11-30
DK153290D0 (en) 1990-06-22
HK166295A (en) 1995-11-03
DK153290A (en) 1990-08-16
WO1989005823A1 (en) 1989-06-29
CA1320163C (en) 1993-07-13
US5288630A (en) 1994-02-22
US5194595A (en) 1993-03-16

Similar Documents

Publication Publication Date Title
FI903154A0 (en) KIMERISKA GLYKOPROTEINER INNEHAOLLANDE IMMUNOGENISKA SEGMENT AV GLYKOPROTEINER AV MAENNISKANS RESPIRATORY SYNCYTIAL VIRUS.
NO904538D0 (en) CHEMICAL GYCLOPROTEINS CONTAINING IMMUNOGENIC SEGMENTS OF HUMANT PARAINFLUENNAVIRUS TYPE 3.
ATE163682T1 (en) RESPIRATORY SYNCYTIAL VIRUS, VACCINES
EP0855918A4 (en) Chicken interleukin-15 and uses thereof
ES500567A0 (en) PROCEDURE FOR PREPARING VACCINATION COMPLEXES BY REACTION OF RIBONOSAL RNA AND SPECIFIC ANTIGENS.
DE60041280D1 (en) CHIMERIC HUMAN CATTLE RESPIRATORY SYNCYTIAL VIRUS VACCINES
EA200100302A1 (en) METHODS AND COMPOSITIONS FOR PROTECTIVE AND THERAPEUTIC GENETIC IMMUNIZATION
ATE101200T1 (en) VACCINES AGAINST HUMAN RESPIRATORY VIRUSES.
KR890700030A (en) Vaccines and diagnostic methods for influenza (Haemophilus influenzae)
ATE234917T1 (en) AVIRULENT SALMONELLA MICROBE WITH A MUTATION IN THE CDT GENE AND THEIR USE
DE3585578D1 (en) HEPATITIS SURFACE ANTI-PARTICLE VACCINE.
MY101874A (en) Vaccine
DE3582422D1 (en) BIOLOGICAL PREPARATIONS.
DK0542895T3 (en) Cross-reactive influenza A immunization

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: PHARMACIA & UPJOHN COMPANY

FG Patent granted

Owner name: PHARMACIA & UPJOHN COMPANY

MA Patent expired